Clinical expertise. Rapid results.

Your path from bench to bedside starts here.

Before a therapy can change lives, it has to prove itself in humans. At Nucleus Network, we run early-phase trials that help sponsors move from first-in-human to proof of concept with speed and confidence. Fast approvals. Reliable execution. Data you can take anywhere.

With dedicated Global early-phase units, we combine clinical precision, regulatory know-how, and hospital-grade care to keep your study on track and on time.

Download our capabilities overview

Nucleus Network acquires Hammersmith Medicines Research

Nucleus Network has acquired Hammersmith Medicines Research (HMR), establishing the first truly global early-phase clinical trial network with dedicated facilities across Australia, the US and the UK.

This strategic milestone unites two leaders in early-phase research, combining deep scientific expertise, operational excellence and a shared commitment to advancing medicine. The expanded global footprint enables faster, more inclusive trials with harmonised processes and streamlined sponsor engagement, delivering high-quality outcomes across three continents.

Read the full press release

Your trusted partner

Global capability. Local precision. Proven results.

Biotech and pharma teams don’t just need a site, they need a partner who delivers with speed, consistency, and global regulatory alignment.

With more than 2,500 Phase 1 trials completed and over three decades of early-phase experience, we’ve built the infrastructure, teams, and trust to move programs forward.

Here’s what sets us apart:

2,500+ Phase 1 Trials Delivered

30+ Years of Early-Phase Experience

Fast Startup Timelines

Globally Accepted, Audit-Ready Data

Global Network of Phase 1 Units

Integrated Recruitment and Special Populations Access

Early phase. Fully delivered.

From first in human to vaccine programs, we tailor every study to your goals.

With more than 2,500 early-phase clinical trials delivered, including over 1,500 first in human studies, Nucleus Network offers unmatched expertise in early phase clinical pharmacology. We support the full spectrum of study designs, from simple single dose studies to complex, protocol intensive trials involving patient populations and proof of concept. Whether you are exploring drug-drug interactions, food effects, or targeted biologics, our teams deliver with precision, care, and regulatory alignment, always tailored to your program’s specific needs.

Explore our study capabilities

Our global footprint

A trusted leader in clinical pharmacology trials, Nucleus Network accelerates drug development with a global network.

Melbourne

Melbourne, Australia

Australia’s largest and most experienced Phase 1 unit and global leader in first-in-human trials.

Our global footprint

A trusted leader in clinical pharmacology trials, Nucleus Network accelerates drug development with a global network.

Brisbane

Brisbane, Australia

Australia’s second largest Phase 1 clinical trial facility and the only phase 1 unit dedicated to early clinical development of New Biological Entities (NBE’s), Biosimilar and Vaccines.

Our global footprint

A trusted leader in clinical pharmacology trials, Nucleus Network accelerates drug development with a global network.

Minneapolis

Minneapolis, United States

Minneapolis delivers Phase 1 trials under U.S. IND, with a focus on renal, hepatic, and patient-specific studies. Strategically positioned in the University Enterprise Laboratories, it offers seamless integration for North American sponsors targeting global submissions.

Our global footprint

A trusted leader in clinical pharmacology trials, Nucleus Network accelerates drug development with a global network.

London

London, United Kingdom

HMR London specialises in early-phase clinical trials under UK and EU regulations, focusing on first-in-human and adaptive study designs. Located in a dedicated facility in West London, it provides integrated clinical, laboratory, and pharmacy services, making it an ideal site for global sponsors seeking rapid, high-quality data for regulatory submissions.

Therapeutic expertise across early-phase and beyond

From healthy volunteers to early patient cohorts, we bring clinical precision to a broad range of indications.

Our therapeutic experience spans metabolic and endocrine disorders, vaccines, respiratory conditions, neurology, cardiology, immunology, rare diseases, and more. Whether a study involves healthy participants or those living with chronic conditions, our teams are equipped to deliver with scientific care, operational agility, and submission-ready quality.

Explore our therapeutic areas

How we deliver differently

Purpose-built facilities. Global-quality data. Real-world readiness.

At Nucleus Network, early-phase isn’t a side offering, it’s our core focus. Our clinics, teams, and systems are designed from the ground up to support fast, high-quality execution with no compromises.

From hospital proximity to patient recruitment and bioanalytical integration, everything is built to move your study forward.

Strategic site locations

Melbourne: co-located with the Alfred Hospital
Brisbane: co-located with the Royal Brisbane and Women’s Hospital
Minneapolis: US biomedical hub with in-clinic dialysis, biomarker sampling, and patient access.

Real-world recruitment strength

In-house marketing and recruitment teams.
Extensive volunteer and special population and patient databases.
Proven success enrolling renal, hepatic, elderly, and metabolic cohorts.

Integrated trial capabilities

Onsite pharmacy and sample prep.
Real-time ECG telemetry and flexible inpatient/outpatient setups.
Imaging partnerships for PD and efficacy endpoints (e.g. MRI-PDFF).

Globally accepted, submission-ready data

Full GCP compliance across all sites.
Regulatory alignment with FDA, EMA, and TGA.
Data accepted for NDA, 505(b)(2), ANDA, and biosimilar filings.

Let’s move your molecule forward

The first step matters. Let’s make it count.

Whether you’re preparing for first-in-human, advancing to proof of concept, or planning a multi-region strategy, we’ll help you reach your next milestone with speed, focus, and global readiness.

Get in touch